Intravenous preadministration of somatostatin (Growth Hormone Inhibiting Factor: GIF) inhibited TRH-induced TSH release in rats anesthesized by pentobarbitulate. There was dose dependent negative interaction between the inhibitory effect of GIF and releasing effect of TRH. TSH releasing effect of small dose of TRH was inhibited completely by preadministration of GIF, while large dose of TRH overcame the inhibitory effect of GIF. The mechanism responsible for inhibitory effect of GIF on TRH-induced TSH release was discussed.
It has been well known that somatostatin (growth hormone inhibiting factor: GIF or somatotropin-release inhibiting factor: SR IF), isolated and synthesized by Paul Brazeau and his coworkers (1973) , lowers circulating level of immunoreactive growth hormone and inhibits the elevation of plasma growth hormone induced by acute administration of pentobarbitulate. Furthermore, it had been reported that synthetic somatostatin inhibited the elevation of plasma TSH induced by synthetic TRH in vitro and in vivo (Abstract 1973 , Hall et al., 1973 ). An attempt was made to study the influence of somatostatin on TRH induced TSH release in rats with special reference to quantitative relation between dose of GIF and TRH in vivo. 
Discussion
It has been well documented that TRH activity might be inhibited or modified by preadministration of several hormones i.e., thyroxine (T4) (Martin et al., 1972) , triiodothyronine (T3) (Vale et al., 1967) , corticosteroid (Otsuki et al., 1973) and estrogen (Carlson et al., 1973) . It seems very interest to declare whether a new synthesized hypothalamic hormone, somatostatin, might has modifying effect on TRH activity or not. Intravenous injection of synthetic somatostatin has inhibitory effect of GH release in man and rats during various GH releasing stimuli, such as insulin induced hypoglycemia (Hall et al., 1973) , acute administration of pentobarbital-Na (Brazeau et al., 1974) , electrical stimulation (Martin et al., 1974) , chlorpromazine (Sawano et al., 1974) , and prostaglandin E1, (Ooshima et al., 1974) . Partial or complete inhibitory effect of somatostatin on TRH induced TSH release were observed in our experiment described before. Since plasma TSH level of rats pretreated with somatostatin was almost the same to that of saline treated rats, resting plasma TSH level was thought to be unaffected by pretreatment of somatostatin. However, plasma TSH response to TRH was less in rats pretreated with somatostatin than in rats treated by saline. On our observation, TRHinduced TSH response was inhibited by the administration of somatostatin in dose of 10 (Hall et al., 1973) .
These results indicate that the inhibitory action of somatostatin on TRH-induced TSH response was dose dependent and comparable to observations in man. The inhibitory mechanism of somatostatin on TRH induced TSH release is not yet clear, but somatostatin may act on receptor of pituitary thyrotroph concerned with TSH release (TRH receptor) to compete with TRH. There are previous reports that administration of TRH induces TSH and prolactin release in man and animals. Hall (1973) had reported that somatostatin inhibited TRH induced TSH release, but not altered TRH induced prolactin release.
Somatostatin presumably competes with TRH for the receptors of pituitary cells related to TSH release but not receptors concerned with prolactin release. It has been already reported that there are negative interaction for TSH release between the dose of T4 and that of TRH: the difinite dose of T4 inhibit the activity of definite dose of TRH, and large dose of TRH overcome the inhibitory action of T4 (Vale et al., 1967) . Since actinomycin D, puromycin and cycloheximide, a kind of protein synthesis inhibitor, prevent the inhibitory effect of T4 (Bower et al., 1968) , it was postulated that newly synthesized protein might be necessary for inhibitory action of T4 (Schally et al., 1968) . It seems necessary to investigate possible metabolic changes occuring in pituitary cells by administration of somatostatin.
